⭐️⭐️⭐️⭐️⭐️ "A total no brainer"

⭐️⭐️⭐️⭐️⭐️ "Love this, so easy."

Spots is the easy way to track your skin, mole and cancer changes.

Spots Global Cancer Trial Database for carcinoma of the head and neck

Every month we try and update this database with for carcinoma of the head and neck cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study titleNCT IDConditionsInterventionsEligibilityOrganizationLink
Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck CancerNCT03733210
Squamous Cell C...
Carcinoma of th...
Panitumumab-IRD...
89-Zirconium (Z...
Pinpoint IR IR9...
SPY-PHI IR9000 ...
Explorer Air ca...
PDE-NEO II came...
FIS-00 fluoresc...
Da Vinci Firefl...
IGP-ELVIS-v4 Ma...
Vevo 3100 LAZR-...
Pearl Triology ...
Odyssey CLx Ima...
Leica fluoresce...
19 Years - Stanford University
Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and NeckNCT00184028
Carcinoma of th...
Taxotere
Oxaliplatin
18 Years - University of Southern California
Intensity-Modulated Radiotherapy for Recurrent Head and Neck CancerNCT00257335
Carcinoma of th...
IMRT
18 Years - University of California, Irvine
Combination of Taxotere and Oxaliplatin in Squamous Cell Carcinoma of the Head and NeckNCT00184028
Carcinoma of th...
Taxotere
Oxaliplatin
18 Years - University of Southern California
Efficacy and Activity of BAY 43-9006 in Patients With Recurrent and/or Metastatic Head and Neck CancerNCT00199160
Head and Neck N...
BAY 43-9006
18 Years - Jules Bordet Institute
Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)NCT00865098
Carcinoma of th...
Cetuximab
20 Years - Merck KGaA, Darmstadt, Germany
Phase II Trial of Allovectin-7® for Head and Neck CancerNCT00050388
Head and Neck C...
Squamous Cell C...
Head and Neck N...
Carcinoma of th...
Allovectin-7®
18 Years - Vical
Accelerated Modulated Fractionation (SIB-IMRT) for Head and Neck DistrictNCT03001570
Carcinoma of th...
Cetuximab plus ...
18 Years - 90 YearsEuropean Institute of Oncology
Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to DrugsNCT04985357
Stage III Breas...
Stage IV Breast...
Stage III Lung ...
Stage IV Lung C...
AML
Multiple Myelom...
Carcinoma
Carcinoma, Panc...
Carcinoma of Lu...
Carcinoma, Non-...
Carcinoma Breas...
Carcinoma Prost...
Carcinoma, Hepa...
Carcinoma, Rena...
Carcinoma, Neur...
Carcinoma, Smal...
Carcinoma, Ovar...
Carcinoma Bladd...
Carcinoma of Es...
Carcinoma Cervi...
Carcinoma, Thym...
Carcinoma, Duct...
Carcinoma of th...
Carcinoma of th...
Carcinoma of th...
Carcinoma of Un...
Carcinoma of th...
Carcinoma of th...
Carcinoma of th...
Carcinoma of th...
Carcinoma of th...
Carcinoma of th...
Carcinoma of th...
Carcinoma of th...
Malignant Pleur...
Malignant Ascit...
Mesothelioma
Cholangiocarcin...
18 Years - Travera Inc
Panitumumab-IRDye800 and 89Zr-Panitumumab in Identifying Metastatic Lymph Nodes in Patients With Squamous Cell Head and Neck CancerNCT03733210
Squamous Cell C...
Carcinoma of th...
Panitumumab-IRD...
89-Zirconium (Z...
Pinpoint IR IR9...
SPY-PHI IR9000 ...
Explorer Air ca...
PDE-NEO II came...
FIS-00 fluoresc...
Da Vinci Firefl...
IGP-ELVIS-v4 Ma...
Vevo 3100 LAZR-...
Pearl Triology ...
Odyssey CLx Ima...
Leica fluoresce...
19 Years - Stanford University
Talimogene Laherparepvec With Pembrolizumab for Recurrent Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY232 / KEYNOTE-137)NCT02626000
Carcinoma of th...
Talimogene Lahe...
Pembrolizumab
18 Years - Amgen
Study of Cetuximab With Concomitant-boost Radiotherapy in Patients With Newly Diagnosed Locally Advanced Squamous Cell Carcinoma of the Head and Neck (SCCHN)NCT00865098
Carcinoma of th...
Cetuximab
20 Years - Merck KGaA, Darmstadt, Germany
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)NCT05461430
Pleural Effusio...
Ascites, Malign...
Carcinoma
Carcinoma, Hepa...
Carcinoma, Rena...
Carcinoma, Rena...
Carcinoma, Smal...
Carcinoma, Non-...
Carcinoma, Panc...
Carcinoma, Neur...
Carcinoma, Thym...
Carcinoma, Panc...
Carcinoma Breas...
Carcinoma, Ovar...
Carcinoma Bladd...
Carcinoma of Un...
Carcinoma of th...
Carcinoma of th...
Carcinoma of th...
Carcinoma of th...
Carcinoma of Es...
Carcinoma of th...
Carcinoma of th...
Carcinoma of th...
Carcinoma of th...
Carcinoma of th...
Carcinoma of th...
Carcinoma of th...
Cholangiocarcin...
Melanoma
Mesothelioma
Pancreatic Canc...
18 Years - Travera Inc
Logo

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

spots app storespots app store

Join others from around the world: